Tim Anderson
Stock Analyst at B of A Securities
(3.81)
# 818
Out of 4,969 analysts
40
Total ratings
66.67%
Success rate
6.62%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tim Anderson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APGE Apogee Therapeutics | Maintains: Buy | $78 → $87 | $38.16 | +127.99% | 1 | Aug 28, 2025 | |
| MTSR Metsera | Maintains: Buy | $45 → $50 | $35.66 | +40.21% | 2 | Aug 28, 2025 | |
| AARD Aardvark Therapeutics | Maintains: Buy | $26 → $25 | $8.18 | +205.62% | 3 | Aug 28, 2025 | |
| PFE Pfizer | Maintains: Neutral | $27 → $28 | $24.79 | +12.95% | 2 | Aug 6, 2025 | |
| AMGN Amgen | Maintains: Underperform | $252 → $261 | $283.85 | -8.05% | 5 | Jul 23, 2025 | |
| JNJ Johnson & Johnson | Maintains: Neutral | $161 → $175 | $178.00 | -1.69% | 6 | Jul 17, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Underperform | $575 → $547 | $563.80 | -2.98% | 2 | Apr 17, 2025 | |
| GILD Gilead Sciences | Maintains: Buy | $116 → $126 | $112.99 | +11.51% | 3 | Mar 5, 2025 | |
| ABBV AbbVie | Maintains: Neutral | $200 → $223 | $211.86 | +5.26% | 5 | Mar 4, 2025 | |
| MRNA Moderna | Maintains: Underperform | $41 → $34 | $24.05 | +41.37% | 2 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $118 → $112 | $84.18 | +33.05% | 4 | Feb 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $63 | $47.50 | +32.63% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $178 | $141.62 | +25.69% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $997 | $737.83 | +35.13% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $128.23 | - | 1 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $82.11 | - | 1 | Sep 22, 2017 |
Apogee Therapeutics
Aug 28, 2025
Maintains: Buy
Price Target: $78 → $87
Current: $38.16
Upside: +127.99%
Metsera
Aug 28, 2025
Maintains: Buy
Price Target: $45 → $50
Current: $35.66
Upside: +40.21%
Aardvark Therapeutics
Aug 28, 2025
Maintains: Buy
Price Target: $26 → $25
Current: $8.18
Upside: +205.62%
Pfizer
Aug 6, 2025
Maintains: Neutral
Price Target: $27 → $28
Current: $24.79
Upside: +12.95%
Amgen
Jul 23, 2025
Maintains: Underperform
Price Target: $252 → $261
Current: $283.85
Upside: -8.05%
Johnson & Johnson
Jul 17, 2025
Maintains: Neutral
Price Target: $161 → $175
Current: $178.00
Upside: -1.69%
Regeneron Pharmaceuticals
Apr 17, 2025
Maintains: Underperform
Price Target: $575 → $547
Current: $563.80
Upside: -2.98%
Gilead Sciences
Mar 5, 2025
Maintains: Buy
Price Target: $116 → $126
Current: $112.99
Upside: +11.51%
AbbVie
Mar 4, 2025
Maintains: Neutral
Price Target: $200 → $223
Current: $211.86
Upside: +5.26%
Moderna
Feb 11, 2025
Maintains: Underperform
Price Target: $41 → $34
Current: $24.05
Upside: +41.37%
Feb 5, 2025
Maintains: Buy
Price Target: $118 → $112
Current: $84.18
Upside: +33.05%
Dec 10, 2024
Reinstates: Neutral
Price Target: $63
Current: $47.50
Upside: +32.63%
Dec 10, 2024
Reinstates: Neutral
Price Target: $178
Current: $141.62
Upside: +25.69%
Dec 10, 2024
Reinstates: Buy
Price Target: $997
Current: $737.83
Upside: +35.13%
May 9, 2022
Downgrades: Peer Perform
Price Target: n/a
Current: $128.23
Upside: -
Sep 22, 2017
Upgrades: Outperform
Price Target: n/a
Current: $82.11
Upside: -